A proprietary–Oxford Biomedica–gene therapy which provides controlled release of erythropoietin–EPO in response to low O2 concentration in patients with chronic, treatment-refractory anaemia.
It is packaged as a viral delivery vector* with the EPO gene under hypoxia-inducible factors–HIF-responsive element–HRE control. HRE senses low oxygen concentrations and switch on the EPO gene.
*Because Repoxgen’s protein is of viral origin, it could evoke a potentially fatal immune response. Repoxygen has the potential for abuse by endurance athletes, but may be of use for “anoxic” sports, including high mountain climbing and deep free diving.